Background: Conventional de novo drug design is costly and time consuming, making it accessible to only the best resourced research organizations. An emergent approach to new drug development is drug repurposing, in which compounds that have already gone through some level of clinical testing are examined for efficacy against diseases divergent than their original application. Repurposing of existing drugs circumvents the time and considerable cost of early stages of drug development, and can be accelerated by using software to screen existing chemical databases to identify suitable drug candidates. Results: Small-molecule Peptide-Influenced Drug Repurposing (SPIDR) was developed to identify small molecule drugs that target a specific recep...
The drug development process consumes 9–12 years and approximately one billion US dollars in costs. ...
A variety of peptides active in biological pathways have been identified e.g. receptor antagonists o...
A variety of peptides active in biological pathways have been identified e.g. receptor antagonists o...
Background: Conventional de novo drug design is costly and time consuming, making it accessible to o...
Background: Conventional de novo drug design is costly and time consuming, making it accessible to o...
Background: Conventional de novo drug design is costly and time consuming, making it accessible to o...
Abstract Background Conventional de novo drug design is costly and time consuming, making it accessi...
Since the discovery of the molecular basis of disease, numerous studies have reported a correlation ...
Since the discovery of the molecular basis of disease, numerous studies have reported a correlation ...
Since the discovery of the molecular basis of disease, numerous studies have reported a correlation ...
Repurposing “old” drugs to treat both common and rare diseases is increasingly emerging as an attrac...
© 2018, The Author(s). Rare, or orphan, diseases are conditions afflicting a small subset of people ...
Interest in peptide drug discovery is surging. In the past several years,numerous pharmaceutical and...
The drug development process consumes 9–12 years and approximately one billion US dollars in costs. ...
The process of discovering a new drug is always evolving with the knowledge, technologies, and needs...
The drug development process consumes 9–12 years and approximately one billion US dollars in costs. ...
A variety of peptides active in biological pathways have been identified e.g. receptor antagonists o...
A variety of peptides active in biological pathways have been identified e.g. receptor antagonists o...
Background: Conventional de novo drug design is costly and time consuming, making it accessible to o...
Background: Conventional de novo drug design is costly and time consuming, making it accessible to o...
Background: Conventional de novo drug design is costly and time consuming, making it accessible to o...
Abstract Background Conventional de novo drug design is costly and time consuming, making it accessi...
Since the discovery of the molecular basis of disease, numerous studies have reported a correlation ...
Since the discovery of the molecular basis of disease, numerous studies have reported a correlation ...
Since the discovery of the molecular basis of disease, numerous studies have reported a correlation ...
Repurposing “old” drugs to treat both common and rare diseases is increasingly emerging as an attrac...
© 2018, The Author(s). Rare, or orphan, diseases are conditions afflicting a small subset of people ...
Interest in peptide drug discovery is surging. In the past several years,numerous pharmaceutical and...
The drug development process consumes 9–12 years and approximately one billion US dollars in costs. ...
The process of discovering a new drug is always evolving with the knowledge, technologies, and needs...
The drug development process consumes 9–12 years and approximately one billion US dollars in costs. ...
A variety of peptides active in biological pathways have been identified e.g. receptor antagonists o...
A variety of peptides active in biological pathways have been identified e.g. receptor antagonists o...